EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors

Xianzhe Yu, Lingling Zhu, Ting Wang, Lu Li, Jiewei Liu, Guowei Che, Qinghua Zhou

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · 2023

DOI: 10.1016/j.bbcan.2023.188910 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2023. Verfasst von Xianzhe Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Lung Cancer Institute/Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China; Department of Ga…. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 196 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The anti-cancer efficacy of anti-malignancy therapies is related to DNA damage. However, DNA damage-response mechanisms can repair DNA damage, failing anti-tumor therapy. The resistance to chemotherapy, radiotherapy, and immunotherapy remains a clinical challenge. Thus, new strategies to overcome these therapeutic resistance mechanisms are needed. DNA damage repair inhibitors (DDRis) continue to be investigated, with polyadenosine diphosphate ribose polymerase inhibitors being the most studied inhibitors. Evidence of their clinical benefits and therapeutic potential in preclinical studies is growing. In addition to their potential as a monotherapy, DDRis may play an important synergistic role with other anti-cancer therapies or in reversing acquired treatment resistance. Here we review the impact of DDRis on solid tumors and the potential value of combinations of different treatment modalities with DDRis for solid tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Poly(ADP-ribose) Polymerase InhibitorsNeoplasmsHumansDNA RepairDNA DamageImmunotherapy

Stichwörter der Autor:innen

DNA damage repair inhibitorImmune checkpoint blockadeSolid cancerpolyadenosine diphosphate ribose polymerase inhibitors

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Lung Cancer Institute/Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China; Department of Gastrointestinal Surgery, Chengdu Second People's Hospital, No. 10 Qinyu…
  • Lung Cancer Institute/Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China.
  • Lung Cancer Institute/Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address: jerry_ljw@163.com.
  • Lung Cancer Institute/Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address: cheguowei_hx@aliyun.com.
  • Lung Cancer Institute/Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China. Electronic address: prof_qh_zhou@126.com.

Zitieren

APA

Yu, X., Zhu, L., Wang, T., Li, L., Liu, J., Che, G., & Zhou, Q. (2023). Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. https://doi.org/10.1016/j.bbcan.2023.188910

Vancouver

Yu X, Zhu L, Wang T, Li L, Liu J, Che G, et al. Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023. doi:10.1016/j.bbcan.2023.188910

BibTeX
@article{Yu2023,
  author = {Yu, Xianzhe and Zhu, Lingling and Wang, Ting and Li, Lu and Liu, Jiewei and Che, Guowei and Zhou, Qinghua},
  title = {Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors},
  journal = {Biochimica et Biophysica Acta (BBA) - Reviews on Cancer},
  year = {2023},
  doi = {10.1016/j.bbcan.2023.188910}
}
Kostenlos starten →